Filana Therapeutics Statistics
Total Valuation
FLNA has a market cap or net worth of $100.96 million. The enterprise value is -$6.08 million.
| Market Cap | 100.96M |
| Enterprise Value | -6.08M |
Important Dates
The next estimated earnings date is Tuesday, March 17, 2026.
| Earnings Date | Mar 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
FLNA has 48.31 million shares outstanding. The number of shares has increased by 7.58% in one year.
| Current Share Class | 48.31M |
| Shares Outstanding | 48.31M |
| Shares Change (YoY) | +7.58% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 11.02% |
| Owned by Institutions (%) | 28.63% |
| Float | 42.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.41 |
| P/TBV Ratio | 1.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.27
| Current Ratio | 2.27 |
| Quick Ratio | 2.22 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -85.44% and return on invested capital (ROIC) is -35.32%.
| Return on Equity (ROE) | -85.44% |
| Return on Assets (ROA) | -24.80% |
| Return on Invested Capital (ROIC) | -35.32% |
| Return on Capital Employed (ROCE) | -85.85% |
| Weighted Average Cost of Capital (WACC) | -0.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.53M |
| Employee Count | 30 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.72% in the last 52 weeks. The beta is -0.84, so FLNA's price volatility has been lower than the market average.
| Beta (5Y) | -0.84 |
| 52-Week Price Change | -21.72% |
| 50-Day Moving Average | 2.12 |
| 200-Day Moving Average | 2.51 |
| Relative Strength Index (RSI) | 46.84 |
| Average Volume (20 Days) | 760,535 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -43.27M |
| Operating Income | -70.13M |
| Pretax Income | -106.03M |
| Net Income | -106.03M |
| EBITDA | -69.30M |
| EBIT | -70.13M |
| Earnings Per Share (EPS) | -$2.20 |
Full Income StatementBalance Sheet
The company has $106.08 million in cash and n/a in debt, with a net cash position of $106.08 million or $2.20 per share.
| Cash & Cash Equivalents | 106.08M |
| Total Debt | n/a |
| Net Cash | 106.08M |
| Net Cash Per Share | $2.20 |
| Equity (Book Value) | 81.57M |
| Book Value Per Share | 1.69 |
| Working Capital | 60.86M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$83.77 million and capital expenditures -$137,000, giving a free cash flow of -$83.91 million.
| Operating Cash Flow | -83.77M |
| Capital Expenditures | -137,000 |
| Free Cash Flow | -83.91M |
| FCF Per Share | -$1.74 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
